Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7763615 | JAZZ | Ecteinascidin analogs for use as antitumour agents |
Dec, 2024
(1 year, 6 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 15, 2025 |
Orphan Drug Exclusivity (ODE) | Jun 15, 2027 |
NCE-1 date: 2024-06-15
Market Authorisation Date: 15 June, 2020
Treatment: Treatment of adult patients with small cell lung cancer (sclc) with disease progression on or after platinum-based chemotherapy.
Dosage: POWDER;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic